Logo
x

Search

Subscribe Now

Moderate

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada Approval for the Treatment of Moderate to Severe Atopic Dermatitis

  • October 8, 2021
AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Erythematosus

AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Er...

  • August 2, 2021
Biogen and Bio-Thera Report Results of BAT1806 (biosimilar- tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis

Biogen and Bio-Thera Report Results of BAT1806 (biosimilar- tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthriti...

  • June 3, 2021
Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

Novartis' Cosentyx (secukinumab) Receives the US FDA's Approval for the Treatment of Moderate to Severe Plaque Psoriasis

  • June 2, 2021
The US FDA Extends Review Period of Olumiant's sNDA to Treat Moderate to Severe Atopic Dermatitis

The US FDA Extends Review Period of Olumiant's sNDA to Treat Moderate to Severe Atopic Dermatitis

  • April 7, 2021
Regeneron and Sanofi Report the US FDA's Acceptance of sBLA for Review of Dupixent to Treat Moderate-to-Severe Asthma in Children

Regeneron and Sanofi Report the US FDA's Acceptance of sBLA for Review of Dupixent to Treat Moderate-to-Severe Asthma in Children

  • March 4, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.